SS Innovations reports preliminary FY25 revenue $43M vs $20.6M last year

SSi Mantra installations of 103, up 119% from 47 installations in 2024. Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations (SSII), commented, “We expect to report strong fourth quarter revenue growth, driven by higher unit sales of our advanced, cost-effective SSi Mantra surgical robotic system in India and abroad. We are committed to democratizing excellence in surgical care on a global scale, including in the United States and Europe. We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for the SSi Mantra in the first half of 2026. We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can obtain in the first half of 2026. We look forward to providing additional financial details when we release our fourth quarter financial results in the latter part of February.”